711 related articles for article (PubMed ID: 31110158)
1. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
2. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
3. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
4. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
5. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
6. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
7. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.
Guan H; You Z; Wang C; Fang F; Peng R; Mao L; Xu B; Chen M
Cancer Med; 2019 Apr; 8(4):1474-1485. PubMed ID: 30784214
[TBL] [Abstract][Full Text] [Related]
9. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
10. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
Martinez RS; Salji MJ; Rushworth L; Ntala C; Rodriguez Blanco G; Hedley A; Clark W; Peixoto P; Hervouet E; Renaude E; Kung SHY; Galbraith LCA; Nixon C; Lilla S; MacKay GM; Fazli L; Gaughan L; Sumpton D; Gleave ME; Zanivan S; Blomme A; Leung HY
Cancer Res; 2021 Jul; 81(13):3664-3678. PubMed ID: 33985973
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
[TBL] [Abstract][Full Text] [Related]
13.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
14. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
16. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
18. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
19. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
20. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
